Patents Assigned to Sangamo Therapeutics, Inc.
  • Compositions for linking DNA-binding domains and cleavage domains
    Patent number: 10538787
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: January 21, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: David Paschon, Lei Zhang
  • FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
    Patent number: 10526610
    Abstract: A method of gene editing or gene stacking within a FAD3 loci by cleaving, in a site directed manner, a location in a FAD3 gene in a cell, to generate a break in the FAD3 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 7, 2020
    Assignees: Dow AgroSciences LLC, Sangamo Therapeutics, Inc.
    Inventors: Noel Cogan, John Forster, Matthew Hayden, Tim Sawbridge, German Spangenberg, Steven R. Webb, Manju Gupta, W. Michael Ainley, Matthew J. Henry, Jeffrey C. Miller, Dmitry Y. Guschin
  • Targeted disruption of the MHC cell receptor
    Patent number: 10500229
    Abstract: Disclosed herein are methods and compositions for inactivating MHC genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: December 10, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Methods and compositions for integration of an exogenous sequence within the genome of plants
    Patent number: 10501748
    Abstract: Disclosed herein are methods and compositions for parallel or sequential transgene stacking in plants to produce plants with selected phenotypes.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: December 10, 2019
    Assignees: Dow AgroSciences LLC, Sangamo Therapeutics, Inc.
    Inventors: W. Michael Ainley, Dmitry Y. Guschin, Matthew Hayden, Daniel Isenegger, John Mason, Jeffrey C. Miller, Joseph F. Petolino, Yidong Ran, Tim Sawbridge, German Spangenberg, Steven R. Webb
  • Delivery methods and compositions for nuclease-mediated genome engineering
    Patent number: 10494648
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: December 3, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Jianbin Wang
  • Methods and compositions for treating Huntington's disease
    Patent number: 10471123
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: November 12, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • Delivery methods and compositions for nuclease-mediated genome engineering
    Patent number: 10450585
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: October 22, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, Brigit E. Riley, Susan J. St. Martin, Thomas Wechsler
  • Genetically modified human cell with a corrected mutant sickle cell mutation
    Patent number: 10435677
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic stem cell.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 8, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Jeffrey C. Miller, Lei Zhang
  • HTT repressors and uses thereof
    Patent number: 10435441
    Abstract: Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: October 8, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Steven Froelich, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Methods and compositions for treating hemophilia
    Patent number: 10407476
    Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins involved in clotting into the genome of a cell for treating conditions including hemophilias.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: September 10, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • Method of treating factor IX deficiency using nuclease-mediated targeted integration
    Patent number: 10370680
    Abstract: Disclosed herein are methods and compositions for targeted, nuclease-mediated insertion of transgene sequences into the genome of a cell.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: August 6, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Thomas Wechsler
  • Methods and compositions for treating Huntington's disease
    Patent number: 10369201
    Abstract: Disclosed herein are methods and compositions for diagnosing, treating or preventing Huntington's Disease.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: August 6, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: H. Steve Zhang
  • Targeted modification of malate dehydrogenase
    Patent number: 10358684
    Abstract: Disclosed herein are methods and compositions for targeted modification of one or more endogenous plant malate dehydrogenase genes.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: July 23, 2019
    Assignees: Dow AgroSciences LLC, Sangamo Therapeutics, Inc.
    Inventors: Vipula Shukla, Manju Gupta, Fyodor Urnov, Dmitry Y. Guschin, Michiel Jan De Both, Paul Bundock, Lakshmi Sastry-Dent
  • Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
    Patent number: 10344289
    Abstract: The present disclosure relates to engineered zinc finger proteins that target 5-enolpyruvyl shikimate-3-phosphate synthase (EPSPS) genes in plants and methods of using such zinc finger proteins in modulating gene expression, gene inactivation, and targeted gene modification. In particular, the disclosure pertains to zinc finger nucleases for targeted cleavage and alteration of EPSPS genes.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 9, 2019
    Assignees: Dow AgroSciences LLC, Sangamo Therapeutics, Inc.
    Inventors: Manju Gupta, Asha M. Palta, Stephen Novak, Fyodor Urnov, Sunita Gopalan
  • Modified zinc finger binding proteins
    Patent number: 10344271
    Abstract: Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: July 9, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Edward J. Rebar, Andrew Jamieson
  • Methods and compositions for the treatment of lysosomal storage diseases
    Patent number: 10293000
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: May 21, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
    Patent number: 10287595
    Abstract: Methods and compositions for gene disruption, gene editing or gene stacking within a FAD2 loci by cleaving, in a site directed manner, a location in a FAD2 gene in a soybean cell, to generate a break in the FAD2 gene and then optionally integrating into the break a nucleic acid molecule of interest is disclosed.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 14, 2019
    Assignees: Dow AgroSciences LLC, Sangamo Therapeutics, Inc.
    Inventors: W. Michael Ainley, Steven R. Webb, Jayakumar P. Samuel, Dmitry Y. Guschin, Jeffrey C. Miller, Lei Zhang
  • Methods and compositions for treating Huntington's Disease
    Patent number: 10265377
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: April 23, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • Targeted genomic alteration
    Patent number: 10260062
    Abstract: Disclosed herein are methods and compositions for targeted integration and/or targeted excision of one or more sequences into a cell, for example, for expression of one or more polypeptides of interest.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: April 16, 2019
    Assignees: Sangamo Therapeutics, Inc., Dow AgroSciences LLC
    Inventors: William M. Ainley, Michael G. Murray, Fyodor Urnov, Bryan Zeitler
  • DNA-binding proteins and uses thereof
    Patent number: 10253333
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: April 9, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang